A Phase 3 interventional study of IVA in Cystic Fibrosis, sponsored by Vertex Pharmaceuticals Incorporated. Completed at 29 sites in 6 countries. Open to participants aged 0 Months to 24 Months. Per ClinicalTrials.gov, last updated 2024-10-23.
Sponsored by Vertex Pharmaceuticals Incorporated · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 84 studies testing ivacaftor in Cystic Fibrosis — 4 open to participants now, 7 under way, 2 of them phase 3. ivacaftor · Cystic Fibrosis.
Among the 84 studies testing ivacaftor in Cystic Fibrosis, this one is the 32nd largest by enrollment, is one of 7 that started in 2017, is one of 45 in phase 3, and was the 52nd registered.
1,621 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.
Browse Cystic Fibrosis studies →4 of the 84 studies testing ivacaftor in Cystic Fibrosis are open now, in 2 countries. Recruiting first, the newest first:
Istituto Giannina Gaslini · Sites in Italy
Ages 6+
Vertex Pharmaceuticals Incorporated · Sites in United States
Ages 18–55 · Healthy volunteers
Vertex Pharmaceuticals Incorporated · Sites in United States
Ages 18–55 · Healthy volunteers
Arkansas Children's Hospital Research Institute · Sites in United States
Ages 3+
By country, each count listing its studies:
ivacaftor: first FDA approval 2012 (KALYDECO), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 86 take children under 18; 41 take healthy volunteers.
This study: 0 Months to 24 Months · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
84 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 18 · Phase 3 45 · Phase 4 7
First in 2007; this study’s year is marked. 7 started in 2017.
This study's enrollment of 86 is above the median of 36 across 1,053 interventional studies indexed under Cystic Fibrosis.
Median enrollment 70 across the 84 interventional studies. Of the 76 that completed or were terminated, 64 (84%) have results posted.
This tab as a report to print or save as PDF → With an account.
74 of 84 have an industry lead sponsor. The 10 most frequent:
Vertex Pharmaceuticals Incorporated is the lead sponsor of 249 studies on the registry; 17 are open to participants now.
Of its 107 completed or terminated interventional studies of FDA-regulated products, 54 (50%) have results posted.
125 studies in Cystic Fibrosis by Vertex Pharmaceuticals Incorporated: 3 open now, 8 under way, 5 of them phase 3. Of 112 finished, 80 (71%) have results posted.
Among the 125 studies in Cystic Fibrosis by Vertex Pharmaceuticals Incorporated, this one is the 50th largest by enrollment of the 116 interventional ones that give a count, is one of 7 that started in 2017, is one of 62 in phase 3, and was the 68th registered.
Vertex Pharmaceuticals Incorporated’s Cystic Fibrosis studies by the year they started, since 2007.
4 of the studies testing ivacaftor in Cystic Fibrosis that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05331183Phase 3Vertex Pharmaceuticals IncorporatedStudy to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508del | 2027-04-06 |
| NCT06460506Phase 3Vertex Pharmaceuticals IncorporatedEvaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis Participants 12 Months of Age and Older | 2027-09-30 |
| NCT07437105Vertex Pharmaceuticals IncorporatedDose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy Participants | 2027-06-26 |
| NCT07283770Vertex Pharmaceuticals IncorporatedEvaluation of VX-581 in Healthy Participants and in Participants With Cystic Fibrosis | 2027-07-12 |
Add all 4 to your calendar (.ics) → With an account.
Among the 84 studies testing ivacaftor in Cystic Fibrosis, from their registry updates:
Among Vertex Pharmaceuticals Incorporated’s 125 in Cystic Fibrosis:
This tab as a report to print or save as PDF → With an account.
This is a Phase 3, 2-arm, multicenter study with an open-label ivacaftor arm and an observational arm to evaluate the safety and efficacy of long-term ivacaftor treatment in participants with cystic fibrosis (CF) who are \<24 months of age at treatment initiation and have an approved Ivacaftor-Responsive mutation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Ivacaftor Arm: Participants From Study 124 (NCT02725567 ) Part B:
Ivacaftor Arm: Participants Not From Study 124 Part B:
Observational Arm:
Exclusion Criteria:
Ivacaftor Arm: Participants From Study 124 Part B:
Ivacaftor Arm: Participants Not From Study 124 Part B:
Observational Arm:
Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants less than (\<) 24 months of age and weighing 5 to less than (\<) 7 kilogram (kg) received 25 mg IVA every 12 hours (q12h), 7 to \<14 kg received 50 mg IVA q12h, and those weighing 14 to \<25 kg received 75 mg IVA q12h. Participants more than or equal (\>=) 24 months of age and weighing \<14 kg received 50 mg IVA q12h, and those weighing more than or equal to (\>=)14 kg received 75 mg IVA q12h in the treatment period for up to 96 weeks. Doses were determined based on safety and pharmacokinetic (PK) data from parent study, age and weight.
Drug: IVA
Granules for oral administration.
Also known as: VX-770, ivacaftor
Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEs
Time frame: Day 1 up to Week 120
Absolute Change in Sweat Chloride
Sweat samples were collected using an approved collection device.
Time frame: From Baseline at Week 96
This study was planned to include 2 arms: an ivacaftor (IVA) arm (open-label, 96-week treatment period) and an observational arm. However, there were no participants enrolled in the observational arm. A total of 86 participants enrolled in the Ivacaftor arm.
| Milestone | Ivacaftor Treatment |
|---|---|
| Started | 86 |
| Rollover participants | 38 |
| Iva-naïve participants | 48 |
| Completed | 58 |
| Not completed | 28 |
| Withdrew: Commercial drug is available for participants | 20 |
| Withdrew: Lost to follow-up | 3 |
| Withdrew: Withdrawal of consent (not due to ae) | 3 |
| Withdrew: Other | 2 |
| Participants | Ivacaftor Treatment |
|---|---|
| Participants with TEAEs | 85 |
| Participants with SAEs | 21 |
Sweat samples were collected using an approved collection device.
| millimole per liter (mmol/L) | Ivacaftor Treatment |
|---|---|
| Absolute Change in Sweat Chloride | -55.3 ± 25.0 |
Collected over Day 1 up to Week 120. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ivacaftor Arm | 0/86 (0%) | 21/86 (24.4%) | 83/86 (96.5%) |
| Event | Ivacaftor Arm |
|---|---|
| Infective pulmonary exacerbation of cystic fibrosisInfections and infestations | 9/86 |
| ConstipationGastrointestinal disorders | 2/86 |
| Pseudomonas test positiveInvestigations | 2/86 |
| Adrenocortical insufficiency acuteEndocrine disorders | 1/86 |
| Distal intestinal obstruction syndromeGastrointestinal disorders | 1/86 |
| PyrexiaGeneral disorders | 1/86 |
| BronchiolitisInfections and infestations | 1/86 |
| BronchitisInfections and infestations | 1/86 |
| GastroenteritisInfections and infestations | 1/86 |
| Gastroenteritis viralInfections and infestations | 1/86 |
| Event | Ivacaftor Arm |
|---|---|
| CoughRespiratory, thoracic and mediastinal disorders | 60/86 |
| PyrexiaGeneral disorders | 34/86 |
| RhinorrhoeaRespiratory, thoracic and mediastinal disorders | 33/86 |
| Upper respiratory tract infectionInfections and infestations | 24/86 |
| VomitingGastrointestinal disorders | 22/86 |
| RashSkin and subcutaneous tissue disorders | 21/86 |
| Ear infectionInfections and infestations | 19/86 |
| DiarrhoeaGastrointestinal disorders | 15/86 |
| ConstipationGastrointestinal disorders | 13/86 |
| Infective pulmonary exacerbation of cystic fibrosisInfections and infestations | 13/86 |
Baseline data was analyzed on safety Set which is defined as all participants who received at least 1 dose of study drug.
| Age, Continuous(months) | Ivacaftor Treatment |
|---|---|
| Mean | 10.2 ± 5.19 |
| Sex: Female, Male(Participants) | Ivacaftor Treatment |
|---|---|
| Female | 40 |
| Male | 46 |
| Race/Ethnicity, Customized(Participants) | Ivacaftor Treatment |
|---|---|
| Hispanic or Latino | 2 |
| Not Hispanic or Latino | 79 |
| Not collected per local regulations | 5 |
| Race/Ethnicity, Customized(Participants) | Ivacaftor Treatment |
|---|---|
| White | 82 |
| Asian | 1 |
| Not collected per local regulations | 3 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Details on Vertex data sharing criteria and process for requesting access can be found at: https://www.vrtx.com/independent-research/clinical-trial-data-sharing
Ran from Aug 2017 to primary completion in Oct 2023, 73 months.
Results were first posted in Oct 2024, 1 year after primary completion.
Of 58 industry-sponsored phase 3 interventional studies under Cystic Fibrosis, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 36. This study's 73 months is above that.
Counting every sponsor, half of 67 studies reached it within 26 months; a quarter within 16 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ivacaftor
Vertex Pharmaceuticals Incorporated →